| Literature DB >> 29772754 |
Robert J Gatchel1, Kelley Bevers2, John C Licciardone3, Jianzhong Su4, Ying Du5, Marco Brotto6.
Abstract
Traditionally, there has been a widely accepted notion that the transition from acute to chronic pain follows a linear trajectory, where an injury leads to acute episodes, subacute stages, and progresses to a chronic pain condition. However, it appears that pain progression is much more complicated and individualized than this original unsupported assumption. It is now becoming apparent that, while this linear progression may occur, it is not the only path that pain, specifically low-back pain, follows. It is clear there is a definite need to evaluate how low-back pain trajectories are classified and, subsequently, how we can more effectively intervene during these progression stages. In order to better understand and manage pain conditions, we must examine the different pain trajectories, and develop a standard by which to use these classifications, so that clinicians can better identify and predict patient-needs and customize treatments for maximum efficacy. The present article examines the most recent trajectory research, and highlights the importance of developing a broader model for patient evaluation.Entities:
Keywords: acute; chronic; low-back pain; pain; pain trajectories; subacute
Year: 2018 PMID: 29772754 PMCID: PMC6023386 DOI: 10.3390/healthcare6020048
Source DB: PubMed Journal: Healthcare (Basel) ISSN: 2227-9032
Figure 1Flow Chart of Background Literature Selection.
Trajectory Classification by Reference Study.
| Authors | Year | Timeline |
| Identified Trajectories | Design | |
|---|---|---|---|---|---|---|
| Dunn, Jordan, and Croft | 2006 | Monthly for 6 months | 342 | 4 | Persistent Mild | Observational |
| Chen, Hogg-Johnson and Smith | 2007 | 4/10/16/52 weeks | 678 | 5 | Continuous High | Observational |
| Kongsted and Leboeuf-Yde | 2009 | Weekly for 18 weeks | 78 | 4 | Worsened then Fluctuating | Observational |
| Tamcan, et al. | 2010 | Weekly for 1 year | 305 | 4 | Persistent Severe | Observational |
| Axen, et al. | 2011 | Weekly for 6 months | 176 | 5 | Typical | Observational |
| Dunn, Campbell and Jordan | 2013 | Monthly for 6 months, at 7 years | 155 | 4 | No/Occasional (recovery) | Observational |
| Lebouef, et al. | 2013 | Every 2 weeks for 1 year | 261 | 3 | More or less Constant | Observational |
| Banez, et al. | 2014 | Admission/Discharge, 1/12/24/48 months | 173 | 4 | Stable Long-term Improvement | Observational |
| Hermsen, et al. | 2014 | Base, 6/12/18 months | 407 | 3 | Observational | |
| Macedo, et al. | 2014 | Monthly for 1 year | 155 | 5 | RCT | |
| Deyo, et al. | 2015 | 3/6/12 months | 3929 | 5 | Stable Low | Observational |
| Downie, et al. | 2015 | 1/2/4/12 weeks | 1585 | 5 | Rapid Recovery | RCT |
| Kongsted, et al. | 2015 | Weekly for 1 year | 1082 | 5 | Mild Episodic | Observational |
| Palermo, et al. | 2015 | Weekly for 8 weeks | 135 | 4 | RCT | |
| Enthoven, et al. | 2016 | Base, 6 weeks, 3/6/9 months, 1/2/3 years | 675 | 3 | Low Pain | Observational |
| Panken, et al. | 2016 | Baseline, 3/6/12 months | 622 (299/134/195) | 3 | Merged 3 RCT Trials Data | |
| Kongsted, et al. | 2017 | Weekly for 1 year | 1271 | 8 | Observational | |
| Chen, et al. | 2018 | 5 years, then 3 monthly | 281 | 4 | Observational | |
| Simons, et al. | 2018 | Admission/Discharge, 1/4/12 months | 253 | 3 | Observational |
Levels of Evidence Ratings of Included Trajectory Studies *.
| Authors | Year of Publication | Level of Evidence Rating |
|---|---|---|
| Dunn, Jordan and Croft | 2006 | II |
| Chen, et al. | 2007 | II |
| Kongsted and Leboeuf-Yde | 2009 | II |
| Tamcan, et al. | 2010 | II |
| Axen, et al. | 2011 | II |
| Dunn, Campbell and Jordan | 2013 | II |
| Lebouef, et al. | 2013 | II |
| Banez, et al. | 2014 | II |
| Hermsen, et al. | 2014 | II |
| Macedo, et al. | 2014 | II |
| Deyo, et al. | 2015 | I |
| Downie, et al. | 2015 | III |
| Kongsted, et al. | 2015 | I |
| Palermo, et al. | 2015 | I |
| Enthoven, et al. | 2016 | III |
| Panken, et al. | 2016 | II |
| Kongsted, et al. | 2017 | III |
| Nielsen, et al. | 2017 | II |
| Chen, et al. | 2018 | II |
| Simons, et al. | 2018 | II |
* Levels of Evidence data were adapted from material published by the Centre for Evidence-Based Medicine, Oxford UK: www.cebm.net. Level I is the highest quality-study, followed by Levels II–V in descending order of quality.